SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-24-000065
Filing Date
2024-02-16
Accepted
2024-02-16 08:02:47
Documents
14
Period of Report
2024-02-16
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20240216.htm   iXBRL 8-K 29500
  Complete submission text file 0001714899-24-000065.txt   155035

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240216.xsd EX-101.SCH 1934
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240216_lab.xml EX-101.LAB 23834
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240216_pre.xml EX-101.PRE 12530
15 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240216_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 24645842
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)